Innoviva, Inc. (INVA) Expected to Post Quarterly Sales of $63.27 Million
Equities analysts expect that Innoviva, Inc. (NASDAQ:INVA) will report sales of $63.27 million for the current quarter, according to Zacks. Two analysts have issued estimates for Innoviva’s earnings, with the highest sales estimate coming in at $65.62 million and the lowest estimate coming in at $60.91 million. Innoviva posted sales of $43.61 million in the same quarter last year, which suggests a positive year over year growth rate of 45.1%. The company is scheduled to report its next earnings results on Thursday, February 8th.
On average, analysts expect that Innoviva will report full-year sales of $63.27 million for the current financial year, with estimates ranging from $208.61 million to $221.78 million. For the next year, analysts anticipate that the firm will report sales of $285.11 million per share, with estimates ranging from $230.43 million to $336.77 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Innoviva.
Innoviva (NASDAQ:INVA) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $0.21 EPS for the quarter, missing analysts’ consensus estimates of $0.34 by ($0.13). The company had revenue of $48.64 million for the quarter, compared to analyst estimates of $57.18 million. Innoviva had a net margin of 52.91% and a negative return on equity of 33.55%. The firm’s revenue was up 46.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.13 EPS.
INVA has been the topic of a number of recent research reports. ValuEngine upgraded Innoviva from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Zacks Investment Research cut Innoviva from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 16th. Cowen and Company set a $16.00 target price on Innoviva and gave the stock a “buy” rating in a report on Friday, July 28th. Robert W. Baird restated a “neutral” rating and issued a $13.00 target price (up from $11.00) on shares of Innoviva in a report on Thursday, July 27th. Finally, Stifel Nicolaus restated a “hold” rating and issued a $15.00 target price on shares of Innoviva in a report on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $13.60.
Several hedge funds have recently modified their holdings of the company. Alps Advisors Inc. grew its holdings in shares of Innoviva by 0.3% during the second quarter. Alps Advisors Inc. now owns 38,232 shares of the biotechnology company’s stock valued at $489,000 after buying an additional 99 shares in the last quarter. Aperio Group LLC grew its holdings in shares of Innoviva by 2.0% during the second quarter. Aperio Group LLC now owns 20,651 shares of the biotechnology company’s stock valued at $264,000 after buying an additional 398 shares in the last quarter. Texas Permanent School Fund grew its holdings in shares of Innoviva by 1.0% during the second quarter. Texas Permanent School Fund now owns 56,687 shares of the biotechnology company’s stock valued at $726,000 after buying an additional 552 shares in the last quarter. Municipal Employees Retirement System of Michigan grew its holdings in shares of Innoviva by 4.0% during the second quarter. Municipal Employees Retirement System of Michigan now owns 18,300 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 710 shares in the last quarter. Finally, Profund Advisors LLC grew its holdings in shares of Innoviva by 8.8% during the second quarter. Profund Advisors LLC now owns 15,220 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 1,227 shares in the last quarter. Institutional investors and hedge funds own 69.73% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/02/innoviva-inc-inva-expected-to-post-quarterly-sales-of-63-27-million.html.
Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with MarketBeat.com's FREE daily email newsletter.